Ashton Thomas Private Wealth LLC Sells 2,365 Shares of Elevance Health, Inc. $ELV

Ashton Thomas Private Wealth LLC lessened its position in Elevance Health, Inc. (NYSE:ELV) by 79.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 622 shares of the company’s stock after selling 2,365 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Elevance Health were worth $201,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Nilsine Partners LLC boosted its holdings in Elevance Health by 1.5% in the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC boosted its stake in shares of Elevance Health by 4.4% in the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after purchasing an additional 31 shares during the last quarter. Detalus Advisors LLC raised its position in shares of Elevance Health by 1.8% in the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after acquiring an additional 31 shares in the last quarter. Forum Financial Management LP boosted its position in shares of Elevance Health by 1.1% during the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after purchasing an additional 33 shares in the last quarter. Finally, Activest Wealth Management grew its stake in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Down 0.6%

Elevance Health stock opened at $325.61 on Wednesday. The firm has a 50 day simple moving average of $351.86 and a 200 day simple moving average of $331.28. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The firm has a market capitalization of $71.87 billion, a price-to-earnings ratio of 12.96, a P/E/G ratio of 1.82 and a beta of 0.50.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Jefferies Financial Group cut their price target on Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a report on Friday, January 30th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Barclays reduced their price target on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Finally, Weiss Ratings lowered shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.